Molly Harper - 29 Dec 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Director
Signature
/s/ Molly Harper
Issuer symbol
CPRX
Transactions as of
29 Dec 2025
Net transactions value
$0
Form type
4
Filing time
30 Dec 2025, 17:00:20 UTC
Previous filing
16 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Harper Molly Director 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES /s/ Molly Harper 30 Dec 2025 0001871470

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +1,334 +57% 3,694 29 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Restricted Stock Units Options Exercise $0 -1,334 -1% $0.000000 127,163 29 Dec 2025 Common Stock 1,334 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Derivative securities vested in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025.
F3 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on December 29, 2025.